miR-130a can predict response to temozolomide in patients with glioblastoma multiforme, independently of O6-methylguanine-DNA methyltransferase

Journal of Translational Medicine

Huyong Zheng³  Wenbin Li¹  Xinyi Li²  Huiyuan Chen¹ 

[1] Cancer Center, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China;University of South Florida, Tampa 33612, FL, USA;Hematology Oncology Center, Beijing Key Laboratory of Pediatric Hematology Oncology, National Key Discipline of Pediatrics, Beijing Children’s Hospital, Capital Medical University, Beijing 100045, China

关键词: MicroRNAs;    Temozolomide;    Glioblastoma;   

Others  :  1132840
DOI  :  10.1186/s12967-015-0435-y

 received in 2014-11-16, accepted in 2015-02-11,  发布年份 2015

【 摘 要 】

Background

Currently, O6-methylguanine-DNA methyltransferase(MGMT) promoter methylation is the most convincing predictive biomarker for temozolomide (TMZ) response in patients with glioblastoma multiforme (GBM). However, technical obstacles prevent this biomarker from being applied widely. On the other hand, microRNAs (miRNAs) are easily investigated in the clinical setting using quantitative real-time polymerase chain reactions. This study aimed to identify miRNAs that could serve as predictive biomarkers for TMZ response.

Methods

The Cancer Genome Atlas (TCGA) and the Chinese Glioma Genome Atlas (CGGA) databases were used to investigate the significance of associations between miRNA expression and overall survival (OS) in TMZ-treated patients with GBM. Cytotoxicity assays were used to validate the miRNAs’ roles in the response of glioma cells to TMZ. Biological insights concerning the miRNAs were explored using gene set enrichment analysis (GSEA) and gene ontology (GO) analysis.

Results

miR-130a was found to be significantly associated with OS in TMZ-treated patients from TCGA and the CGGA. In contrast, miR-130a appeared to be unassociated with OS in patients who only received radiotherapy. The TMZ cytotoxicity assay showed that miR-130a over-expression could sensitize response to TMZ in glioma cells. GSEA and GO analysis indicated that lower miR-130a could generate a more extensive response to oxidative stress, which in turn could elevate Ape1 and mediate resistance to TMZ. In vitro experiment verified that cells with lower miR-130a express higher Ape1 under oxidative stress.

Conclusions

Our data suggested that miR-130a could be a predictive marker for TMZ response in patients with GBM, independently of the mechanism by which MGMT acts as a biomarker. miR-130a could serve as a guide for treatment strategy selection in cases of GBM.

【 授权许可】

   
2015 Chen et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352(10):987-96.
• [2]Hegi ME, Liu L, Herman JG, Stupp R, Wick W, Weller M, et al.: Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol 2008, 26(25):4189-99.
• [3]Weller M, Stupp R, Reifenberger G, Brandes AA, van den Bent MJ, Wick W, et al.: MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat Rev Neurol 2010, 6:39-51.
• [4]von Deimling A, Korshunov A, Hartmann C: The next generation of glioma biomarkers: MGMT methylation, BRAF fusions and IDH1 mutations. Brain Pathol 2011, 21:74-87.
• [5]Hao W, Qiang L, Tao C, Yu-dan C, Fan L, Zhi-fei W: MiR-136 modulates glioma cell sensitivity to temozolomide by targeting astrocyte elevated gene-1. Diagn Pathol 2014, 9:173. BioMed Central Full Text
• [6]Cristina Q, Davide M, Giuseppina R, Giulia R, Angel DL, Margherita I, et al.: miR-221/222 Target the DNA Methyltransferase MGMT in Glioma Cells. Plos One 2013, 8(9):e74466.
• [7]Zhang W, Zhang J, Hoadley K, Kushwaha D, Ramakrishnan V, Li S, et al.: miR-181d: a predictive glioblastoma biomarker that downregulates MGMT expression. Neuro-Oncology 2012, 14(6):712-9.
• [8]Lan J, Xue Y, Chen H, Zhao S, Zhijian W, Fang J, et al.: Hypoxia-induced miR-497 decreases glioma cell sensitivity to TMZ by inhibiting apoptosis. FEBS Lett 2014, 588:3333-9.
• [9]Deepa K, Valya R, Kimberly N, Tyler S, Thien N, Diahnn F, et al.: A genome-wide miRNA screen revealed miR-603 as a MGMT-regulating miRNA in glioblastomas. Oncotarget 2014, 5(12):4026-39.
• [10]Qiang Liu, Ran Zou, Rouxi Zhou, Chaofan Gong, Zhifei Wang, Tao Cai, Chaochao Tan, and Jiasheng Fang. miR-155 Regulates Glioma Cells Invasion and Chemosensitivity by p38 Isforms in vitro. Journal of Cellular Biochemistry 2014, doi: [10.1002/jcb.25073].
• [11]Yan-chang S, Jing W, Cheng-cheng G, Ke S, Jian W, Fu-rong C, et al.: miR-181b sensitizes glioma cells to teniposide by targeting MDM2. BMC Cancer 2014, 14:611. BioMed Central Full Text
• [12]The Cancer Genome Atlas database [http://cancergenome.nih.gov]
• [13]Chinese Glioma Genome Atlas database [http://www.cgga.org.cn]
• [14]DAVID [http://david.abcc.ncifcrf.gov/home.jsp]
• [15]Gene Set Enrichment Analysis [http://www.broadinstitute.org/gsea/]
• [16]Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al.: Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005, 102:15545-50.
• [17]Acunzo M, Visone R, Romano G, Veronese A, Lovat F, Palmieri D, et al.: miR-130a targets MET and induces TRAIL-sensitivity in NSCLC by downregulating miR-221&222. Oncogene 2012, 31(5):634-42.
• [18]Zhou Y-M, Liu J, Sun W: MiR-130a Overcomes Gefitinib Resistance by Targeting Met in Non-Small Cell Lung Cancer Cell Lines. Asian Pacific J Cancer Prevent 2014, 15(3):1391-6.
• [19]Mitra S: MGMT: a personal perspective. DNA Repair 2007, 6:1064-70.
• [20]Tubbs JLJL, Pegg AE, Tainer JA: DNA binding, nucleotide flipping, and the helix-turn-helix motif in base repair by O6-alkylguanine-DNA alkyltransferase and its implications for cancer chemotherapy. DNA Repair 2007, 6:1100-15.
• [21]Loeb LA, Preston BD: Mutagenesis by apurinic/apyrimidinic sites. Annu Rev Genet 1986, 20:201-30.
• [22]Sutton MD, Walker GC: Managing DNA polymerases: coordinating DNA replication, DNA repair, and DNA recombination. Proc Natl Acad Sci U S A 2001, 98:8342-9.
• [23]Yuan F, Zhang Y, Rajpal DK, Wu X, Guo D, Wang M, et al.: Specificity of DNA lesion bypass by the yeast DNA polymerase η. J Biol Chem 2000, 275:8233-9.
• [24]Evans AR, Limp-Foster M, Kelley MR: Going APE over ref-1. Mutat Res 2000, 461:83-108.
• [25]Wilson DM III, Barsky D: The major human abasic endonuclease: formation, consequences, and repair of abasic sites in DNA. Mutat Res 2001, 485:283-307.
• [26]Bobola MS, Blank A, Berger MS, Stevens BA, Silber JR: Apurinic/apyrimidinic endonuclease activity is elevated in human adult gliomas. Clin Cancer Res 2001, 7:3510-8.
• [27]Bapat A, Glass LS, Luo M, Fishel ML, Long EC, Georgiadis MM, et al.: Novel small-molecule inhibitor of apurinic/apyrimidinic endonuclease 1 blocks proliferation and reduces viability of glioblastoma cells. J Pharmacol Exp Ther 2010, 334(3):988-98.
• [28]Silber JR, Bobola MS, Blank A, Schoeler KD, Haroldson PD, Huynh MB, et al.: The Apurinic/Apyrimidinic Endonuclease Activity of Ape1/Ref-1 Contributes to Human Glioma Cell Resistance to Alkylating Agents and Is Elevated by Oxidative Stress. Clin Cancer Res 2002, 8:3008-18.
• [29]Bobola MS, Kolstoe DD, Blank A, Chamberlain MC, Silber JR: Repair of 3-methyladenine and abasic sites by base excision repair mediates glioblastoma resistance to temozolomide. Frontiers Oncol 2012, 2:176. 1–8
• [30]Layton ME, Pazdernik TL: Reactive oxidant species in piriform cortex extracellular fluid during seizures induced by systemic kainic acid in rats. J Mol Neurosci 1999, 13:63-8.
• [31]Ziche M, Morbidelli L: Nitric oxide and angiogenesis. J NeuroOncol 2000, 50:139-48.